drugset / Trial / NCT07691242

Multiple Ascending Dose Study of DW4421

NCT07691242

Phase 1 Not yet recruiting 56 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelBasic science

Summary

Multiple Ascending Dose of DW4421, phase I

Timeline

Start
2026-09
Primary completion
2026-12
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DW4421 Unknown 5 mg Oral
Subject DW4421 Unknown 15 mg Oral
Subject DW4421 Unknown 20 mg Oral
Subject DW4421 Unknown 30 mg Oral
Subject DW4421 Unknown 40 mg Oral
Comparator Zastaprazan Unknown 20 mg Oral

Indications

No indication recorded.